MiR-34a inhibits colon cancer proliferation and metastasis by inhibiting platelet-derived growth factor receptor α

Molecular Medicine Reports
Chunyan LiBo Song

Abstract

The microRNA (miRNA), miR‑34a is significant in colon cancer progression. In the present study, the role of miR‑34a in colon cancer cell proliferation and metastasis was investigated. It was found that the expression of miR‑34a in colon cancer tissues and cell lines was lower when compared with that of normal tissues and cells. Further research demonstrated that miR‑34a inhibited cell proliferation, induced G1 phase arrest, and suppressed metastasis and epithelial mesenchymal transition in colon cancer cells. Bioinformatic prediction indicated that platelet‑derived growth factor receptor α (PDGFRA) was a potential target gene of miR‑34a and a luciferase assay identified that PDGFRA was a novel direct target gene of miR‑34a. In addition, assays of western blot analyses and quantitative reverse‑transcription polymerase chain reaction confirmed that miR‑34a decreased PDGFRA mRNA expression and protein levels in colon cancer cells. Assessment of cellular function indicated that miR‑34a inhibited colon cancer progression via PDGFRA. These findings demonstrate that miR‑34a may act as a negative regulator in colon cancer by targeting PDGFRA.

References

Sep 1, 1987·Journal of Clinical Pathology·J R Jass, B C Morson
Jan 11, 2005·Lancet·Jürgen WeitzMarkus W Büchler
Mar 25, 2006·Nature Reviews. Cancer·Aurora Esquela-Kerscher, Frank J Slack
Oct 25, 2006·Nature Reviews. Cancer·George A Calin, Carlo M Croce
May 23, 2007·Journal of Cell Science·Massimo NegriniCarlo M Croce
Sep 19, 2007·Proceedings of the National Academy of Sciences of the United States of America·Hiroshi TazawaHitoshi Nakagama
Sep 27, 2007·Molecular Cancer·William C S Cho
Feb 27, 2008·Journal of Internal Medicine·T Dalmay
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Munekazu YamakuchiCharles J Lowenstein
May 23, 2009·Cell Death and Differentiation·H Hermeking
Sep 16, 2011·Cancer Research·Can Liu, Dean G Tang
Dec 14, 2011·Journal of Biochemical and Molecular Toxicology·Fei Chen, Shen-Jiang Hu
Mar 19, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ju-Won RohAnil K Sood
Apr 8, 2014·Cytokine & Growth Factor Reviews·Jean-Baptiste Demoulin, Ahmed Essaghir
May 9, 2014·Experimental Cell Research·Anna-Maria StockFrank Entschladen
Sep 4, 2014·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Agnieszka Dyzmann-Sroka, Julian Malicki

❮ Previous
Next ❯

Citations

Jul 27, 2017·Future Oncology·Alexandra Pender, Robin L Jones
Sep 29, 2018·International Journal of Molecular Sciences·Grzegorz HibnerTomasz Francuz
Jan 27, 2017·Frontiers in Genetics·Aida Martinez-SanchezMathieu Latreille
Jun 28, 2018·Cancer Biomarkers : Section a of Disease Markers·Yiqun HuangHongpu Chen
Jan 2, 2019·World Journal of Gastroenterology : WJG·Marcela Alcântara ProençaAna Elizabete Silva
May 8, 2021·Cancer Metastasis Reviews·Sijing LiLi Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.